Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer

dc.contributor.authorRapoport, Bernardo Leon
dc.contributor.authorArani, Ramin B.
dc.contributor.authorMathieson, Nicola
dc.contributor.authorKrendyukov, Andriy
dc.date.accessioned2019-11-14T12:27:32Z
dc.date.available2019-11-14T12:27:32Z
dc.date.issued2019-05
dc.description.abstractAIM : This meta-analysis compared incidence of grade 3-4 neutropenia with ALK inhibitors versus chemotherapy in patients with non-small-cell lung cancer. MATERIALS AND METHODS : PubMed/MEDLINE was searched to identify Phase II and III randomized clinical trials published up to 25 October 2018. Summary incidence, relative risk and corresponding 95% CIs were calculated for grade 3-4 neutropenia. RESULTS : Five randomized clinical trials were included. Relative risk (95% CI) of developing grade 3-4 neutropenia with ALK inhibitor versus chemotherapy was 0.27 (0.07-1.06). Probabilities of developing grade 3-4 neutropenia were 6.56 and 14.19%, respectively; no significant difference was found. CONCLUSION : In patients with non-small-cell lung cancer, incidence of grade 3-4 neutropenia with ALK-targeted therapy is not significantly different compared with chemotherapy.en_ZA
dc.description.departmentImmunologyen_ZA
dc.description.librarianhj2019en_ZA
dc.description.sponsorshipThis meta-analysis was funded by Hexal AG, Holzkirchen, Germany. B Rapoport has received grants from Sandoz, personal fees from Amgen South Africa, Roche Malaysia, Teva and Cipla South Africa.en_ZA
dc.description.urihttps://www.futuremedicine.com/loi/fonen_ZA
dc.identifier.citationRapoport, B., Arani, R.B., Mathieson, N. et al. 2019, 'Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer', Future Oncology, vol. 15, no. 18, pp. 2163-2174.en_ZA
dc.identifier.issn1479-6694 (print)
dc.identifier.issn1744-8301 (online)
dc.identifier.other10.2217/fon-2018-086
dc.identifier.urihttp://hdl.handle.net/2263/72288
dc.language.isoenen_ZA
dc.publisherFuture Medicineen_ZA
dc.rights© 2019 BL Rapoport, RB Arani, N Mathieson, A Krendyuko. This article is published open access.en_ZA
dc.subjectAlectiniben_ZA
dc.subjectALK inhibitoren_ZA
dc.subjectAnaplastic lymphoma kinaseen_ZA
dc.subjectCeritiniben_ZA
dc.subjectChemotherapyen_ZA
dc.subjectCrizotiniben_ZA
dc.subjectNeutropeniaen_ZA
dc.subjectNon-small-cell lung canceren_ZA
dc.subjectTargeted therapyen_ZA
dc.subjectNon-small-cell lung carcinoma (NSCLC)en_ZA
dc.subjectAnaplastic lymphoma kinase (ALK)en_ZA
dc.titleMeta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung canceren_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Rapoport_MetaAnalysis_2019.pdf
Size:
1.4 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
Thumbnail Image
Name:
Rapoport_MetaAnalysisSuppl_2019.pdf
Size:
282.73 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Material
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Immunology)
Research Articles (University of Pretoria)
Simple item page